Ms. Abhita Batra, MS, MBA, serves as the Chief Executive Officer and Director at Otomagnetics. Abhita is also the Founder and Managing Director of Advanced Biopharma Consulting (ABC), a strategic advisory firm that offers business development and commercialization services to life science companies. Previously, she served as the Vice President of Business Development and Marketing at Admac Group of Companies, wherein she managed a product portfolio encompassing 150 generics. She is a co-founder and former COO of Navya, a biotechnology company developing and commercializing PHF for destruction of solid tumors. Abhita completed her Global MBA at UCLA Anderson and NUS, and has a Masters in Biotechnology with specialization in Pharmaceutical Sciences from University of Pennsylvania. Dr. Benjamin Shapiro, PhD, is a Full Professor at the Fischell Department of Bioengineering at the University of Maryland, College Park. He is the inventor of the magnetic injection technology and is currently responsible for the operations for Otomagnetics. He has helped raise over $6M in non-dilutive grant funding for the effort thus far. Dr. Didier Depireux, PhD, is member of the faculty at the Institute for Systems Research at the University of Maryland. As co-founder and chief scientific officer of Otomagnetics, he is the hearing and neuroscience expert, leading the animal model research. Mr. Beylin, MS, MBA, is co-founder of Otomagnetics and serves on the company's board of directors. Mr.Beylin is a CEO of Brain Biosciences, Inc., a medical imaging company, which he co-founded. Previously, Mr.Beylin served as a Program Director at the National Cancer Institute, an Entrepreneur-in-Residence at X/Seed Capital, and a VP of Research at Naviscan PET Systems. Specialties: Medical technology start-ups, university spin-outs, commercialization of medical devices, early stage fund-raising. Mr. Dushyant Chipalkatty, also known as Chip, founded PACK Pharmaceuticals, LLC in 2005 and serves as its President of Global Business Development. Mr. Chipalkatty previously worked as the Chief Operating Officer of Morton Grove Pharmaceuticals, Inc. since 1999. He has over 28 years of experience in the pharmaceutical technology field. He joined Morton Grove Pharmaceuticals, Inc. from Carter-Wallace in Cranbury, New Jersey. and worked at Carter Wallace from 1979 -1999. He has extensive experience in operational cGMP, cost control and plant modernization. At Morton Grove, Mr. Chipalkatty is responsible for supply chain and technology management. He has a Bachelor's in Pharmacy and Masters in Pharmacy (Pharmacognosy) degree from Nagpur University, India and a Master's degree in Pharmaceutical Sciences from Rutgers University. Ms. Neela Chipalkatty is a seasoned life sciences and real-estate investor. She brings over thirty years of operational experience in biotechnology and pharmaceutical industries to Otomagnetics. Neela is a technology and business expert who has led the implementation of quality systems at Bristol Myers Squibb, Barr Laboratories, Sandoz and Reed and Carnrick, division of Block Drugs. Neela has an undergraduate degree in Chemistry and law from Bombay University. She also holds a Masters degree in International Law with focus on Global Affairs from NYU. Dr. Jerome Lewis, MBA PhD, is co-inventor of all three AMAG approved drug products, Feraheme, Feridex I. V. and GastroMark and several other drug products at various stages of development. Feraheme and Feridex are FDA-approved nanoparticle products, and have been used to treat millions of patients. At AMAG, Dr. Lewis was Head of Chemistry R&D and was responsible for product development,scale-up, and manufacturing of all products during development and for commercial sales. He was responsible for the manufacturing and microbiological sections of NDAs and INDs, both US and foreign. Dr. Irving Weinberg MD, PhD, is the President of Weinberg Medical Physics and a Cofounder of Otomagnetics. Dr. Weinberg has spent two decades launching startups in the medical device field. He has had a part in launching four FDA-approved products and he served as Chief Technology Officer and President of Naviscan PET Systems, Inc. His early career began as an experimental plasma physicist at the University of California at Irvine. He is a member of advisory boards at UCLA and George Mason University.